Report on how AI is redefining market landscape - The global gastroparesis drugs market size is estimated to grow by USD 1.42 ...

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.

Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Bernstein analyst Miki Sogi maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) yesterday and set a price target ...

Eisai has argued that maintenance dosing with Leqembi will prolong treatment benefits by targeting protofibrils, a toxic form of beta-amyloid.

Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Eisai Co (ESAIY) and Biogen Inc. (BIIB) announced that the latest findings for lecanemab-irmb, an anti-amyloid beta protofibril* antibody for the treatment of early Alzheimer’s disease, were presented ...

Biogen reported mixed third-quarter results, with EPS beating expectations despite a decline in total revenue.

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. | All told, third-quarter U.S. Leqembi sales grew 33% over the prior quarter to $39 ...

Biogen stock dipped Wednesday despite an unexpected boost from its new Alzheimer's drug, Leqembi, and an earnings guidance hike.